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SCREENING OF CRUDE MICROALGAL EXTRACTS FOR ANTIMICROBIAL ACTIVITY 
 
 
Patrick T. Matulich 
 
University of the Incarnate Word, 2019 
 
 
Microbial biofilm associated infections are a significant threat to patients with medical 
devices and are partially responsible for the increased resistance seen in nosocomial infections. 
The biofilm chemical and physical properties restrict access of chemotherapeutic agents. 
Therefore, there is a need to enhance the antimicrobial effects of current chemotherapeutic 
agents. Microalgae live in competitive environments that include film-forming, opportunistic 
pathogens S. maltophilia and C. albicans. Extracts from 5 diverse species of microalgae were 
screened for antimicrobial enhancing effects against established biofilms with two different 
extraction solvents, 3:1 hexanes and isopropyl (HIPA) and 2-methyltetrahydrofuran (2-MTHF). 
 Three species, B. braunii, C. danica, and N. oculata showed statistically significant 
reduction in cell viability of S. maltophilia in an established biofilm (p < 0.001, p < 0.001, and p 
< 0.001, respectively). An extract of 2-MTHF, N. oculata [M], showed enhancing effects of 
ceftriaxone against S. maltophilia in an established biofilm. Furthermore, B. braunii, C. danica, 
and N. oculata extracts showed a statistically significant reduction in cell viability of C. albicans 
in combination with fluconazole (p = 0.003, p = 0.002, and p = 0.021, respectively). Based on 
our findings, additional research should focus on the organic components of N. oculata, B. 
braunii, C. danica that contribute to reduced microbial cell viability in established biofilms. 
Furthermore, data suggests that 2-MTHF is a viable solvent for future extraction processes. 
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 Bacteria are an expansive group of microscopic prokaryotic organisms. They are found 
everywhere, including environments previously thought to uninhabitable.1–3 Despite their 
immense genetic diversity, bacteria share common structural features (see Figure 1.0). One of the 
most studied and medically important structures is the bacterial cell wall. All bacteria species 
have a cell wall made of a peptidoglycan, a sugar and protein polymer. The cell wall is rigid to 
provide structural support, and has components that are vital to cell-to-cell communication.4 
 












   
 
 Gram Negative. The broadest way to categorize bacterial species is based on their cell 
wall structure. The thickness of this cell wall helps categorize bacteria as gram-positive or gram-
negative. A gram-positive bacterium has a thick peptidoglycan cell wall that easily retains crystal 
violet (see Figure 2a). Conversely, a gram-negative bacterium has a significantly thinner cell 
wall. In addition, gram-negative organisms have a lipopolysaccharide (LPS) outer membrane 
which covers the cell wall (see Figure 2b). The differences in cell wall structure are crucial in 










Figure 2. Gram-positive 
cell wall structure derived 
from Irving’s Medical 
Microbiology.4 Original 








Figure 3. Gram-negative 
cell wall structure derived 
from Irving’s Medical 
Microbiology.4 Original 





   
 
 Bacterial Resistance. As early as the 1940s, when penicillin was introduced to the 
market, there was already limited evidence of a reduced sensitivity to the beta-lactam over 
time.8,9 These first signs of insensitivity to antibiotics foreshadowed the imminent rise of the 
modern resistance era. Yet, the long-term effects of resistance were largely dominated by our 
ability to find new antibiotics. However, in the 1960’s drug discovery slowed greatly while 
resistance continued to accumulate (see Figure 3).10,11 Now, the world is facing a surge in 
antimicrobial resistance which is, again, shifting our paradigm of treatment options. 
 
Figure 4. Timeline of drug discovery vs. the emergence of resistance to select antibiotics. 
Timeline was created with Adobe Illustrator. Data for the timeline was obtained through the 
CDC’s 2013 report “Antibiotic Resistance Threats in the United States” 12 
 
 Physical Resistance. Many antibiotics target the rigid, peptidoglycan cell wall of 
bacteria.13 Through cell wall disruption, the bacteria’s structure becomes unstable and vulnerable 
to lysis from external pressures. However, gram-negative bacteria have an outer-membrane that 
restricts access to the cell wall through pores. The LPS is a significant physical barrier for novel 
antibiotics, and has limited the number of effective compounds against gram-negative 
bacteria.5,6,14 The physical membrane surrounding the cell provides a rudimentary level of 




   
 
 Genetic Resistance. In recent decades, genetic resistance has exploded into a global 
crisis due to the exponential increase in incidence and accumulation of  resistance genes within 
microbes.12 Resistance genes can be integrated into the single chromosome of a bacteria or, more 
often, are located on an extrachromosomal plasmid (R plasmid).15,16 As reviewed by Van Hoek, 
resistance genes have varying degrees of effectiveness, specificity, and often number in the 
hundreds.17 R plasmids can accumulate resistance genes; in turn, making an organism multidrug 
resistant (MDR). Through the selective pressures of antibiotics, R plasmids are now seen at 
much higher rates in nature.15 
 Horizontal gene transfer. Horizontal gene transfer (HGT) is a ubiquitous mechanism of 
almost all bacteria and involves the exchange of genetic material across species or strains.18–20 
HGT is vital to the evolutionary progression of bacteria. Nearly all resistance genes in bacteria 
are found on transposable elements or linked to transposable elements within the genome. The 
transposable nature of resistance genes means that they are capable of being easily integrated 
into a genome (see Figure 4).15,16,18,20–22 Thus, through HGT a resistant pathogen can transfer the 
associated resistance genes to another species. HGT is not limited to resistance genes. It is also 
attributed in conferring virulence factors that make non-pathogenic bacteria pathogenic.15,16,20 
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Figure 5. Accumulation of genetic resistance via conjugation. 1) When bacterial cells come 
within proximity, they can exchange genetic information through a pili. This method of genetic 
exchange is called, conjugation. Bacterial cells can transfer copies of their plasmid to a cell that 
lacks a plasmid. 2) Resistance genes are located on transposable elements which can easily be 
translocated back and forth between the chromosome and plasmid. A plasmid can accommodate 
multiple genes to confer multi-drug resistance. 3)A plasmid with resistance genes can be 
transferred to a non-plasmid cell, again, through conjugation. 4) Resistance genes have now been 




   
 
Fungi 
 Fungi represent a completely different biological set of microbes and are classified under 
the Eukarya domain accordingly. Their life cycle, molecular structures, and metabolisms are 
radically different than bacteria. Unlike bacteria, fungi have defined membrane bound 
organelles, which are also found in animal cells (see Figure 5).4 Due to the cellular similarities 
between fungi and humans, treatment options for serious fungal infections are limited and carry a 
high risk of toxicity.23–25  
 Often, fungal infections are associated with superficial skin infections, but they can cause 
much more serious illnesses through invasive fungal infections (IFI). Diagnosis of fungal 
infections is often delayed because they are relatively less common in contrast to viral and 
bacterial infections but trigger similar initial symptoms. All these factors lead to dangerous 
mortality rates among mycotic associated infections, as high as 95% in some instances.26,27 
 
 
Figure 6. General structure and components of a fungal cell derived from Irving’s Medical 














   
 
 Most fungal species live commensally in the environment and on other organisms. When 
disturbances occur in the normal flora of an organism or its immune system becomes 
compromised, these commensal fungi can cause dysfunction or disease. In most instances, 
invasive fungal infections are seen in immunocompromised or immunosuppressed patient 
populations: HIV/AIDS patients, cancer patients, and transplant recipients.26–28 Misdiagnosis of 
invasive fungal-related deaths has made it difficult to accurately estimate its impact, but, as 
reviewed by Brown, IFIs account for more deaths than malaria or tuberculosis annually. 
 Fungal Resistance. The number of effective antifungal agents is significantly less than 
antibiotics, with a total of five different classes used for IFIs: azoles, echinocandins, polyenes 
and pyrimidines.24 Nevertheless, antifungal agent discovery and resistance share motifs with 
antibiotics and bacterial resistance. Many antifungal drugs were discovered in the 60s, but many 
IFIs are now showing decreased sensitivity to them.25,28,29 Fungal resistance is of great concern 
because of the limited number of safe, effective drugs available. 
 As opposed to bacterial binary fission, fungi undergo sexual reproduction. Thus, the 
resistance genes do not spread through HGT, but through recombination of genes. The genes can 
then be carried through populations without dominant expression. There are several genetic 
based mechanisms that help fungi avoid destruction by chemotherapeutic agents, mainly drug 
efflux pumps.28,30,31 However, another mechanism of clinical significance is its robust ability to 
form biofilms, which are discussed shortly. 
Biofilms 
 Bacteria and fungi are capable of adhering tightly to biotic and abiotic surfaces through 
the formation of biofilms.32–35 Biofilms are complex infrastructure made of extracellular 
proteins, polysaccharides, and genetic material. The biofilm creates a protective haven for the 
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founding organisms and other microbes, bacterial or fungal. Through the formation of a biofilm, 
a diverse community of organisms can exchange genetic information, store nutrients, and protect 
themselves from physical removal and chemotherapeutic agents (Figure 6).28,30,33,35–37 
 Formation. A major challenge to combating resistant microbes are their ability to form 
biofilms.  Bacterial biofilm formation is moderated by cellular appendages like flagella and pilli 
(see Figure 1). Biofilms are established in the presence of a viable surface and hospitable 
 
Figure 7. The process of biofilm formation and its contributions to antibiotic resistance. 1)In 
favorable conditions, bacteria can begin the process of adhesion to a surface, 2) once attached, 
the bacteria begins excreting the components to form a biofilm, 3) the newly formed surface 
promotes adhesion of other transient bacteria, 4a) the microbial community shares genes through 
horizontal gene transfer, 4b)the mature biofilm confers resistance to antibiotics (ABX), 




   
 
living conditions, such as a water source. Thus, medical devices are a primary source of biofilm 
related infections.31,38–40 
 Once a surface is detected, the organism begins to undergo genetic changes that promote 
film-specific cellular processes. The organism adheres to the surface through excretion of surface 
binding proteins.30,35 In addition to the binding proteins, the organism may secrete a range of 
long polysaccharide chains, extracellular proteins, genetic material, and fatty acids creating an 
extracellular matrix (ECM).30,33,41 The ECM encases the cells—creating a protective barrier from 
the environment and a favorable surface for additional cellular adherence. As more cells attach 
and new generations form, they contribute to the construct of the biofilm. The film can store 
nutrients, send cellular signals, and protect the microbes physical and chemically. Additionally, 
the biofilm shields microbes from therapeutic drug concentrations and the host immune 
cells.33,35,37,41 
 Persister Cells. Upon establishment of an ECM, some cells will undergo drastic changes 
in their genetic expressions.30,33,35,42 They lower their metabolic activity and begin to upregulate 
proteins specific to biofilm maintenance. These metabolically inactive cells are called persister 
cells, and exist as a fundamental element in many fungal and bacterial biofilms.43,44 The ECM 
protects persister cells from exposure, and their slowed metabolism greatly reduces the efficacy 
of chemotherapeutic agents. Their presence helps to continue cell proliferation within the 
biofilm.  
Economic Implications of Resistant Infections 
 The economic burden of resistant infections is difficult to measure, and there continues to 
be debate on how to properly calculate its effects. However, according to a report released by the 
CDC, the direct cost of resistant infections is estimated at $20 billion with an additional $25 
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billion of indirect cost.12,29 In response to the inflating cost associated with resistance, the US has 
increased regulations on antimicrobial prescriptions. Regulatory solutions like this may help curb 
the rapid growth of resistance across microbes, but ultimately has dampened interest in 
antimicrobial research.45–47 If novel compounds are discovered, they likely will be used as a last 
resort—limiting their profitability. 
 Health Disparities. Many first-line antimicrobials can be produced on a commercial 
scale at relatively low cost; providing an efficient means of delivering healthcare to low-income 
and middle-income citizens, especially to those in developing nations. Due in part to their 
widespread, unregulated use, antibiotic resistance is becoming more common among such 
populations.12,18 Since treatment for resistant organisms is often more expensive, the progression 
of resistance is creating a more rigid health disparity worldwide. 
Antimicrobial Agents 
 Antibiotics. As far back as 300 CE, there is evidence that humans had discovered 
mysterious, natural healing powers among soil dwelling fungi.22  However, our understanding of 
the microbial world and the ability to isolate such compounds limited their potential until the 
early 20th century. With the commercialized success of penicillin in 1942, the “Golden Age” of 
antibiotics had begun.8,14,46 
 The widespread success of penicillin in preventing infection related deaths was quickly 
followed by the discovery of streptomycin in 1943, which became the first treatment effective 
against tuberculosis.7,48 While penicillin was synthesized from a fungus, Penicillin notatum, 
streptomycin was synthesized from a soil bacterium, actinomycetes. These first discoveries 
provided a framework for future antibiotic research and led scientists to scour soil 
microenvironments for additional antibiotic producing microbes.14 Through the 1960’s hundreds 
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of antibiotics were discovered this way, representing up to twenty different classes. The scope of 
this research includes agents from two of these classes, monobactams and cephalosporins which 
are structurally related. 
 β-lactams. β-lactams are a copious class of antibiotics that are all feature derivatives of a 
beta-lactam ring. Due to the numerous members in this broad class, they are further divided into 
four sub-classes based on chemical substituents around the beta-lactam ring: penicillins, 
cephalosporins, carbapenems, and monobactams (see Figure 7a-d).7 They all share a similar 
mode of action—inhibiting cell wall synthesis through interactions with penicillin binding 
proteins (PBPs).11 PBPs are membrane bound proteins that are essential to the growth of a 
bacterium. As the cell divides through binary fission, it must rapidly synthesize the growing cell 
wall. The cell wall, made mainly of a complex sugar peptidoglycan, is synthesized in part by 
PBPs which help cross-link rigid, foundational units. β-lactams are, structurally, similar to these 
foundational units; thus, PBPs have an affinity to bind with them.7,10,49,50 In turn, the enzyme 
becomes inactivated, which ultimately prevents further cross-linking within the cell wall.15 The 
result is a weakened cell wall that is susceptible to external pressures and cell lysis. 
 
Figure 8. General structure for penicillins. Public 
domain image. 
 
Figure 9. General structure for 
carbapenems. Public domain image. 
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Figure 10. General structure for cephalosporins. 
Public domain image. 
 
Figure 11. General structure for 
monobactams. Created with ChemDraw 
Professional 16 
 
 Aztreonam. Monobactams, are a relatively small subclass of beta-lactams. They are easily 
identified by the singular four-membered beta-lactam ring. They are of significant clinical 
significance for a couple of reasons: 1) their relatively simple structure enables total synthesis, 
and 2) they are highly specific to penicillin-binding protein 3 (PBP-3).7,11,13,49 Aztreonam (see 
Figure 8) was the first of this subclass to be introduced in 1986. Its fully synthetic nature lowers 
instances of allergic reactions found in traditional beta-lactams that are produced by fungi—
penicillins and cephalosporins.7,9,11 It is freely soluble in water, and has a narrow specificity for 
mostly aerobic, gram-negative bacteria due to its interaction with PBP-3.51 This feature helps to 
reduce disruptions in normal flora of the host, which occurs commonly with other antibiotics. 
 
Figure 12. Chemical structure of aztreonam. Note the beta-lactam ring with substituents, and no 








   
 
 Ceftriaxone. Analogous to the sub-class of penicillins, cephalosporins were discovered as 
a natural product of a fungus, Cephalsporium.52 As with other β-lactams, they comprise of a 
beta-lactam ring with extensive modifications to the side-chains that interfere with cell wall 
synthesis. Cephalosporins have progressed since their first discovery in the 1940s through 
synthetic modifications, and are now classified as generations: first, second, third, and fourth.52,53 
Ceftriaxone (see Figure 9), a water-soluble, third-generation cephalosporin, is known for its 
effectiveness against gram-negative bacteria through interaction with PBPs.53–55 Its introduction 
in the 1980’s helped treat bacterial infections that had become insensitive to penicillins. 
 
Figure 13. Chemical structure for ceftriaxone. Note the central beta-lactam ring with an 
additional fused ring and side chains. Public domain image. 
 
 Antifungals. As mentioned, antifungals present a greater challenge in therapeutic use 
because of the cellular similarities between fungal cells and animal cells. Thus, many effective 
antifungals pose a serious risk of toxicity to patients. Rising resistance to first-line treatment and 
limited classes of safe antifungal agents has begun to strain the capacity for positive outcomes 
from IFIs.28,31,56–58  
 Fluconazole (see Figure 10) is part of the azole class of antifungal agents that target the 
ergosterol biosynthesis pathway by inhibiting a cytochrome P450 (CYP51) enzyme lanosterol 
14-α-demethylase (EC 1.14.13.70).25,58 Ergosterol is an essential membrane component unique 
to fungi. However, CYPs exhibit widespread expression among eukaryotes, and are particularly 
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important in human liver cells where they participate in xenobiotic metabolism and 
detoxification. Thus, interactions of azole antifungals with P450 enzymes present drug 
interaction risks stemming from their interference with the metabolism of other drugs.59,60 It 
remains a common first line treatment because of its low cost and broad specificity. 
Fluconazole’s widespread use has led to increasing resistance among common fungal genera, 
especially Candida— with 7% of Candida clinical isolates currently demonstrating resistance to 
fluconazole.61 
 
Figure 14. Fluconazole chemical structure. Public domain image. 
 
Microalgae 
 Microalgae represent an incredibly diverse group of photoautotrophic and heterotrophic 
unicellular organisms that live in marine, freshwater, or damp soil environments.62,63 Compared 
to other microbial species, microalgae grow slowly and are labor intensive to maintain. However, 
interest in natural products has returned in recent years as a means of offsetting biofuels 
production costs with secondary products and applications. Microalgae species are now used in 
an array of applications including: biofuel production, wastewater treatment, livestock feed, 
cosmetics, nutraceuticals, and antimicrobial compounds.23,64–69  
 Algal Extracts. Macroalgae and microalgae species have been shown to possess quorum-
quenching metabolites, and to interact with bacterial populations.70,71 Quorum-quenching 
molecules are capable of disrupting microbial cell-signaling. Moreover, studies have identified 
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that algal-associated bacteria are often capable of producing quorum-quenching and bactericidal 
compounds.72 Extracts of algal cells are rich in known compounds (antioxidants, flavonoids, and 
polyphenols) that exhibit diverse effects such as: anti-inflammatory, anti-cancer, or antimicrobial 
activity.67,68,73–78 Methods for extracting such active components are as diverse as the algae 
themselves. 
 Antioxidants. Antioxidants represent a broad class of molecules capable of neutralizing 
reactive oxygen species (ROS) and are found naturally in many plants and algae. Through 
routine cellular processes, ROS can readily form and cause damage to cellular components. For 
this reason, a great deal of research in has focused on using antioxidants to prevent cellular 
damage and reduce cancer risks.73,79 Yet, antioxidants have also been recognized for their 
antimicrobial activity in plants. For example, phytoalexins are a group of polyphenolic 
compounds that accumulate in localized fungal, viral, or bacterial infections in plants.80–82 
 Polyphenols. Polyphenols are a well-studied, diverse group of secondary metabolites 
produced in plants. They are produced as biproducts of metabolic cellular processes, but  are 
considered essential for the plant’s survival— in particular, as part of their arsenal of defense 
mechanisms against fungi, bacteria, viruses, and herbaceous predators.83–86 Polyphenols are 
released in response to stressors, infection or predation as a means of preventing further 
damage.87,88 
 According to Stéphane Quideau, a polyphenol must be derived from a phenylpropanoid 
and/or the polyketide pathway, feature more than one phenolic unit, and be deprived of a 
nitrogen-based functionality.84 With these guidelines, polyphenols are further divided into 
subgroups based on chemical structure: flavonoids, nonflavonoids, tannins, and lignins.89,90 In 
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general, these compounds are soluble in polar solvents but exhibit limited water solubility. 
Therefore, they are typically extracted using methanol or ethanol (see Figure 11a-c).66,85  
 
Figure 15. Quercetin. A flavonol 
found in many vegetables. Public 
domain image. 
 
Figure 16. Quercitannin. A tannin 







Figure 17. Nobiletin. A flavonoid 




Context of Study 
Stenotrophomonas maltophilia 
 S. maltophilia is an aerobic, gram-negative, film-forming bacterium that ubiquitous in 
humid or wet environments and colonizes biotic and abiotic surfaces. It is abundant on many 
natural surfaces including human skin but is typically non-pathogenic. However, S. maltophilia 
has emerged as an increasingly common opportunistic pathogen, especially among 
immunocompromised populations.38,91–93 Since it is a gram-negative bacterium, there are limited 
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effective chemotherapeutic agents available to combat S. maltophilia infections. Furthermore, 
genomic analysis has indicated potential resistance mechanisms for a number of antibiotic 
classes that are well conserved.91  With limited treatment options and mortality rates for chronic 
S. maltophilia infections as high as 70 percent, S. maltophilia is evolving in both an attractive 
and urgent target for intervention. 91,94,95 
 Biofilm Properties. S. maltophilia forms robust biofilms on surfaces, biotic and abiotic 
which greatly increase its resistance to antibiotic targeting.94,96–98 It’s adherence to surfaces is 
dependent on hydrophobic properties.  Studies show that the flagellum, pilli, and fimbriae 
increase its ability to attach to abiotic, hydrophobic surfaces. Visualization of the 3-D EPS 
structure shows complex layering of cells and extracellular components with localized 
hydrophobic regions.99,100 Cells within the biofilm have an increased hydrophobicity relative to 
those grown planktonically.99 The hydrophobic nature of the cells and biofilms may account for 
reduced sensitivity to antibiotics since most drugs must be hydrophilic to be distributed 
throughout the body.101  
 At-Risk Populations. S. maltophilia is an emerging pathogen that continues to be 
isolated more frequently in hospital acquired infections due to its affinity for damp environments 
and ability to colonize a wide variety of surfaces.12 It’s efficient development of resistance 
means that the regular use of prophylactic broad-spectrum antibiotics in these patients helps 
creates a non-competitive growth environment for S. maltophilia to colonize and infect.102 
Medical devices are a common means of transmission, including endoscopes, suction hoses, and 
central venous catheters.38,92,98 Unsurprisingly, most clinical isolates are found among critical 
care patients with compromising injuries where these devices are in frequent use, along with 
broad spectrum antibiotics, for long periods of time. Recent findings suggest that the 
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prophylactic use of broad-spectrum antibiotics may contribute significantly to resistant S. 
maltophilia infections.94 
 Like other opportunistic pathogens, S. maltophilia is a serious concern for patients 
without an active immune system—a population that is rapidly growing in modern healthcare 
settings.27 High-risk patients include those with organ or tissue transplantation, HIV/AIDS, 
cystic fibrosis, and cancer. S. maltophilia in these patients is most commonly isolated from upper 
respiratory infections; but is also linked to bacteremia, urinary tract infections, and meningitis.91 
Candida Albicans 
 Candida albicans is a fungus that is ubiquitous in the environment that often lives 
commensally on skin and areas of the gastrointestinal tract.103 Normally, C. albicans goes 
unnoticed and does not disturb its human hosts. However, it is also the main cause of candidiasis, 
which can present in the mouth (thrush), vagina (yeast infection), or systemically (invasive 
candidiasis).104 Invasive candidiasis has a particularly high mortality rate of 19-24%. 
Furthermore, resistance to the first-line drug, fluconazole, is increasing, due in part to the ability 
of C. albicans to form biofilms.61 
 C. albicans forms robust biofilms on biotic and abiotic surfaces, and is the most common 
fungal species isolated from clinical biofilms.104 Through the establishment of a biofilm, the 
fungus can evade both the immune system and antifungal agents. As with S. maltophilia, a 
primary source for nosocomial invasive candidiasis are medical devices such as central venous 
catheters, urinary catheters, heart valves, and endotracheal tubes.103  
 It has been well documented that C. albicans naturally has a hydrophobic cellular surface 
through the expression of the cellular surface hydrophobicity (CHS1) gene.105–107 C. albicans 
hydrophobicity is enhanced through the process of biofilm formation, and is linked to increased 
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virulence.101 Current research demonstrates that hydrophobic compounds have had impacts on 
biofilm formation in C. albicans species.108 
 S. maltophilia and C. albicans are two very different opportunistic pathogens. Yet, they 
are both capable of forming biofilms with hydrophobic properties as a prelude to developing 
drug resistant, both can reside competitively in similar natural environments, and both organisms 
afflict the same human populations.  
Microalgal Extracts 
 Many studies have begun investigating natural sources to enhance antimicrobial activity 
of current treatments to pathogens.109–113 Microalgae have already repeatedly shown antibacterial 
activity.67,114–117 Algal extracts offer an ideal alternative to increasing traditional interventions 
because many species have been labeled as generally accepted as safe (GRAS) and are fully 
biodegradable.63 Furthermore, they offer an efficient, environmentally friendly method of 
producing potentially complex molecules.118,119 However, there remains large classes of species 
which have evaded investigation. The current study uses several species that represent diverse 
classes of microalgae (see Figure 13 and Table 1). Our goal is to evaluate known algae species to 
determine novel applications and stimulate additional research interest for their antimicrobial 
use. We evaluate their efficacy on planktonic growth and established biofilms as compared to 
current antibiotics. Additionally, we determine if algae extracts offer enhancing effects when 
combined with antibiotics or antifungals, against S. maltophilia and C. albicans, respectively. 
It’s theorized that components of the algal extracts can increase the effectiveness of the select 
antimicrobials by negating resistance features of bacterial biofilms and their hydrophobic effects. 
Recent studies have shown that extracts from lipid producing species such as B. braunii, C. 
danica, and N. oculata have measurable antimicrobial effects.115,117,120 However, most of these 
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studies have not evaluated the impact on organisms in biofilms, and have not included the gram-
negative bacterium S. maltophilia or fungus C. albicans. 
Table 1. Algae Species of Interest to the Present Study. 
Algae Species Aquatic Environment Current Interest or Use 
Botryococcus braunii Freshwater Biodiesel121,122 
Tisochrysis lutea Marine Aquaculture feedstock123 
Rhodomonas lens Marine Aquaculture feedstock124,125 
Chlorochromonas danica Freshwater Treatment of waste products126,127 
Nannochlropsis oculata Freshwater Biodiesel128,129 
 
 
Figure 18. Taxonomical reference of algal species used in current study. Figure is a visual 
representation of taxonomy for species and does not depict actual genetic distance or variation 
between species shown. All data was collected from algaebase.org, April 1, 2017. Original image 
created with Adobe Illustrator. 
 
Extraction Solvents 
 As with many natural extract experiments, the choice of solvent plays a crucial role in 
proper evaluation. A majority of active components are found in organic layers of extraction. 
However, it is known that the naturally produced polyphenols and flavonoids have antimicrobial 
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activity, and are extracted best with slightly polar solvents.84,130 Therefore, most extraction 
methods use a mixed solvent system, using a small amount of polar solvent with a large amount 
a non-polar counterpart. One common application is a 3:1 or 3:2 ratio of hexanes-isopropyl or 
chloroform–methanol.131 To simplify this process, 2-methyltetrahydrofuran (2-MTHF) is 
proposed as a singular solvent in comparison with a mixed solvent method employing hexanes-
isopropanol (3:1). 2-MTHF is significantly more polar than hexanes, but less polar than 
isopropyl alcohol according to the solvent polarity scale.132,133 Thus, it should perform similarly 
or slightly better than traditional HIPA solvents in extraction of active organic components. 
Additionally, 2-MTHF is considered a green-solvent because of its low environmental impact, its 
recovery capacity in reactions, and its renewable sourcing.132,134,135 
Material and Methods 
Microalgae  
 All species of algae were obtained from NCMA Bigelow Laboratory and UTEX as 
axenic cultures. Algal cultures were maintained as axenically as possible in media and lighting 
conditions described by the manufacturer to produce a 4-liter culture with a cell concentration of 
6 x 106 per mL. Prior to pelleting, algal cultures were tested for the presence of bacteria using 
PCR (Appendix A). Species used in this study include: Botryococcus braunii 572, 
Nanochloropsus oculata 2164, Rhodomonas lens 739, Tisochrysis lutea 463 and 
Chlorochromonas danica 3279. Algal growth media, enriched seawater (L1), modified Bold’s 
3N medium (MB3N), Erdschreiber’s medium, tris-acetate-phosphate (TAP), and Ochromonas 
media, were prepared in lab using recipes obtained from the National Center of Marine Algae 




   
 
Table 2. Algae Species and Extracts 
Algae Species (UTEX/NCMA ID) Extraction Solvent Label 
Tisochrysis lutea (463) HIPA T. lutea [H] 
Tisochrysis lutea (463) 2-MTHF T. lutea [M] 
Rhodomonas lens (739) HIPA R. lens [H] 
Rhodomonas lens (739) 2-MTHF R. lens [M] 
Botryococcus braunii (572) HIPA B. braunii [H] 
Botryococcus braunii (572) 2-MTHF B. braunii [M] 
Chlorochromonas danica (3279) HIPA C. danica [H] 
Chlorochromonas danica (3279) 2-MTHF C. danica [M] 
Nanochloropsus oculata (2164) HIPA N. oculata [H] 
Nanochloropsus oculata (2164) 2-MTHF N. oculata [M] 
 
Bacterial Cultures  
 Bacterial cultures were grown and stored at 30o C in nutrient broth (NB). 
Stenotrophomonas maltophilia 13637 was obtained from ATCC and grown in nutrient broth 
overnight to a McFarland standard of 0.5.  
Fungal Cultures  
 Cultures of Candida albicans wild-type SC5314 were generously donated by Dr. 
Cristopher Pierce at the University of the Incarnate Word, Biology Department. Yeast cultures 
were grown at 30o in YPD. 
Chemicals  
 All chemicals used were reagent grade, including 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 2,2’-azinobis-(3ethylbenzothiazolin-6-sulfonic acid) 
diammonium salt (ABTS), Folin-Ciocalteu’s reagent, 6-hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid (Trolox), potassium persulfate, gallic acid, 2-(3,4-dihydroxyphenyl)-3,5,7-
trihydroxy-4H-chromen-4-one (quercetin), crystal violet (CV), 2-methyltetrahydrofuran (2-
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MTHF), and aluminum chloride (AlCl3). All buffers, media, antibiotics, and solvents were 
obtained from Sigma Aldrich or Cayman Chemicals. 
Pelleting and Extraction  
 Extraction was completed as described in Pane with slight modification.67 Briefly, upon 
reaching a threshold of 6 x 106 cell per mL in a 4-liter volume, algal cultures were centrifuged 
for 20 min at 3500 rpm and -4o C. The resulting cell pellets were stored at -80oC for no longer 
than 4 weeks. Each pellet was evenly divided for extraction with either 3:1 hexanes/isopropanol 
(HIPA) or 2-methyltetrahydrofuran (2-MTHF). Extraction with either solvent was initiated with 
a volume of solvent equal to the volume of the pellet to be extracted. Each pellet was then 
sonicated for 5 minutes on ice, and centrifuged at 5000 rpm for 10 min at -4o C. The process was 
repeated with additional equivalents of solvent until the pellet showed significant color loss. The 
resulting organic layer was stored in a clean glass vial and its solvent was evaporated under 
stream of air. The final crude extraction residue was reconstituted in 2mL of acetonitrile and 
stored at -60o C.  
Determining Crude Extraction Component Concentration  
 The mass of the extracted residue from each algal culture was determined by transferring 
500µL of its reconstituted extract to a pre-weighed glass vial and evaporating the solvent to yield 
a portion of the original extracted residue. This residue was weighed to obtain a crude extracted 
mass, then reconstituted in 500µL of acetonitrile.    
 Antioxidant Capacity Assay. The total antioxidant capacity (TAC) of extracts was 
evaluated using an ABTS●+ method specialized for evaluating highly pigmented algal 
extracts.136,137 A standard curve was generated using a water-soluble vitamin E derivative, Trolox 
(4µM-0.05µM; R2 = 0.9581). Absorbance was measured at 734nm, for 6 minutes. The TAC 
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reported for each extract was obtained by determining the difference in the absorbances at 6 min 
for the extract and the corresponding absorbance for the ethanol control (negative quench 
control) Difference in absorbances was then used in reference to Trolox standards, and the 
results expressed as micromolar Trolox equivalents per gram of crude extracted residue (mcM 
TE/g).  
 Estimation of Phenolic Content in Crude Algal Extracts. Total phenol concentration 
was determined using Folin-Ciocalteu method.136 A 1:10 dilution of Folin-Ciocalteau reagent (F-
C) was made with water. Briefly, 100µL of F-C was added to either 10µL of extract and 10µL of 
ethanol or 20µL of ethanol (negative phenolic control) in triplicate wells of a 96-well 
polystyrene plate and incubated at room temperature for 4 minutes. Then, 80µL of saturated 
sodium carbonate was added to all wells, and the plate incubated at room temperature for an 
additional 2 hours. Absorbance was measured at 765 nm. A standard curve was generated using 
a gallic acid (0.40-0.025 mg/mL) with an R2=0.9452. Measurements were then expressed as 
milligram equivalents of gallic acid per gram crude extracted residue (mg GAE/g). 
 Determination of Flavonoid Content. The flavonoid content was estimated according to 
the method of Ordonez et al.138 A stock solution of quercetin was created in ethanol 
(0.25g/500mL), and a 2% w/v solution of AlCl3. Briefly, 10 µL of extract or 10 µL of ethanol 
(as negative control) were added to 40µL of ethanol and 50 µL of AlCl3 solution (2% w/v) a 96-
well polystyrene plate and incubated for 1 hr at room temperature. A standard curve was 
prepared using dilutions of quercetin (0.025mg/mL-0.001mg/mL; R2=0.9175). Flavonoid content 
is expressed as milligram equivalents of quercetin per gram crude extracted residue (mg QE/g). 
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Biofilm Formation Assay 
 Biofilm formation assays using crystal violet staining were carried out in 96-well 
polystyrene plates as previously described by O’Toole.30 Control samples contain 10µL of 
acetonitrile instead of 10µL of extract. Absorbance measurements were made in stained wells at 
570nm. Each extract and control were carried out in triplicate for two separate trials. 
 Established Biofilm Assay. S. maltophilia biofilms were prepared in 96-well polystyrene 
plates according to O’Toole and verified by absorbance of rinsed wells at 600nm to verify value 
greater than 0.5. Dilutions of antibiotics were prepared in NB to make the following media 
concentrations: 128µg/mL Aztreonam, 64µg/mL Ceftriaxone, and 32µg/mL of Gentamycin. 
Each antibiotic media (100µL) was added to filmed wells with either 10µL of extract or 10µL of 
ethanol (negative control). Additional control groups were maintained with 10µL of pure 
solvent, acetonitrile. Plates were incubated for 24 hours, washed with PBS three times, and 
stained for 15 minutes with crystal violet. Stained wells were rinsed three times with water and 
the remaining stain solubilized in 30% acetic acid. Absorbance measurements were performed at 
570 nm. Results are the average of triplicates from two trials. 
 The established biofilm assay procedure was followed for C. albicans, with the following 
minor modifications: a cell count of 6 x 108 cells/mL was established for the overnight C. 
albicans stock culture grown in yeast extract peptone dextrose (YPD); and YPD medium was 
replaced with RPMI for biofilm assays and overnight incubation at 37o C.  
 Cell Viability Assay. Cell viability was measured in biofilm formation assays and in 
established biofilm assays by treatment of live cultures with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) according to the manufacturer’s protocol. The procedures 
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for both assays were as described above but with MTT treatment and incubation in place of CV 
staining. Absorbance measurements were performed at 570 nm.  
 Planktonic Growth Assay. Overnight cultures of S. maltophilia were grown in NB at 
30oC, diluted (1:100) in NB, and added (100 µL) to each well of a 96-well polystyrene plate. To 
the diluted culture was added either 10µL of extract, 10µL of extract dilution (1:1, 1:10, 1:100), 
10 µL of acetonitrile (negative control) or 10 µL of an antibiotic dilution (256µg/mL, 128µg/mL, 
64µg/mL, and 32µg/mL).  Plates were incubated for 16 hours at 30oC. Absorbance 
measurements were made at 570nm to determine planktonic growth. Planktonic growth assay 
data is given in Appendix B. 
 Statistics. Spectroscopy measurements were made using Tecan Infinite 200 Pro plate 
reader. Results are displayed as means with error bars representing standard deviation. All 
experiments were carried out twice, independently. Biofilm assays were completed in triplicates, 
while planktonic growth rate was completed in duplicates. All data was compiled and analyzed 
using IBM SPSS 25. Analysis was conducted using one-way analysis of variance (ANOVA) 
with post-hoc Dunnets and Tukey’s test, Kruskal-Wallis, and Mann-Whitney U tests. All 
statistical significance was determined at p < 0.05. Statistical analyses are presented in Appendix 
C. 
RESULTS 
Comparison of Solvents  
 The mass of extracted residue from each algal culture pellet and each of the extraction 
solvents, 3:1 (v/v) hexanes/isopropanol (HIPA) or 2-methyltetrahydrofuran (MTHF) was 
determined as described in the Materials and Methods section (Table 3). The amount of crude 
material extracted from the selected species may reflect the differential solubility of molecular 
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components expected from the selected algal species in these two solvent systems. Both B. 
braunii and C. danica gave significantly less crude extract with HIPA as extraction solvent than 
with MTHF. Extraction masses were similar between the two solvents for the other species 
tested. 
Table 3. Crude Extracted Mass 
 
Algal Extract Extracted Mass  
(mg) 
T. lutea [H] 21.2 
T. lutea [M] 25.2 
R. lens [H] 7.6 
R. lens [M] 9.2 
B. braunii [H] 14.8 
B. braunii [M] 23.6 
C. danica [H] 12.0 
C. danica [M] 29.2 
N. oculata [H] 10.4 
N. oculata [M] 10.8 
 
As described in Table 4, the MTHF extracts had significantly higher polyphenol concentrations 
relative to the corresponding HIPA extracts for all species tested. ANOVA indicates that solvents 
had a statistical significance when comparing total phenolic concentration (p = 0.008). The 





   
 











T. lutea [H] 330.3 ± 1.7 39.3 ± 3.8 10.3 ± 5.7 
T. lutea [M] 324.7 ± 3.1 56.7 ± 6.0 6.2 ± 2.8 
R. lens [H] 102.4 ± 1.8 26.4 ± 0.6 9.7 ± 2.3 
R. lens [M] 187.9 ± 3.4 111.7 ± 3.3 7.4 ± 2.0 
B. braunii [H] 289.7 ± 1.6 58.6 ± 0.7 4.7 ± 0.6 
B. braunii [M] 303.9 ± 2.7 116.7 ± 3.1 2.2 ± 6.6 
C. danica [H]  111.0 ± 0.3 34.1 ± 0.4 3.8 ± 0.6 
C. danica [M] 229.2 ± 1.4 111.2 ± 5.6 10.4 ± 3.4 
N. oculata [H] 105.9 ± 2.3 52.5 ± 2.0 4.4 ± 0.6 
N. oculata [M] 126.8 ± 2.8 81.4 ± 2.3 6.5 ± 0.4 
 aStandardized to Trolox regression and presented as µM Trolox equivalents (TE) per g. 
bStandardized to gallic acid regression and presented as mg gallic acid equivalents (GAE) per g. 
cStandardized to quercetin regression and presented as mg quercetin equivalents (QE) per gram. 
± indicates standard deviation. 
 
Impact on Planktonic Growth 
 Planktonic cultures of S. maltophilia were treated with crude algal extracts according to 
the method described by the Clinical and Laboratory Standards Institute as a means of assessing 
the sensitivity of free-living cells to growth inhibition or bactericidal activity in the extracts. The 
undiluted extract along with three dilutions (1:1, 1:10, and 1:100) in acetonitrile were examined. 
For verification, the same method was used to determine a minimum inhibitory concentration 
(MIC) for gentamicin, aztreonam, and ceftriaxone.  None of the algal extracts tested showed 
significant planktonic growth inhibition, and the sensitivity of planktonic S. maltophilia to the 
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antibiotics tested was as expected, with aztreonam demonstrating the least effective growth 
inhibition of S. maltophilia (Appendix B). 
Impact on Biofilm Formation in S. maltophilia 
 Because biofilm formation in S. maltophilia has been demonstrated to involve signal 
mediation through the diffusible signal factor (DSF) system, the disruption of the filming process 
by a crude algal extract may indicate interference with the DSF machinery by components within 
the extract.139 Therefore, the formation of biofilm by S. maltophilia was evaluated with and 
without the presence of crude algal extracts, examining both the relative mass of formed biofilm 
and the cell viability within the formed film.  
As indicated in Table 5, there was not a significant reduction in the formation of the 
biofilms created by S. maltophilia. The addition of extract before the formation of a biofilm had 
little effect on the organism’s ability to generate a biofilm. 
Table 5. Impact of Extracts on Biofilm Formation by S. maltophilia. 
 
Extract Normalized Film Biomassab 
T. lutea [H] 83.8%  ± 6.6 
T. lutea [M] 83.5%  ± 3.4 
R. lens [H] 89.4%  ± 4.8 
R. lens [M] 92.5%  ± 11.9 
C. danica [H] 73.3%  ± 6.8 
C. danica [M] 80.3%  ± 11.2 
N. oculata [H] 85.5%  ± 12.0 
N. oculata [M] 84.6%  ± 17.5 
B. braunii [H] 82.0%  ± 10.7 
B. braunii [M] 81.2%  ± 8.6 
aAll percentages are normalized to untreated S. maltophilia and ± represents standard deviation. 
bBiomass is estimated from CV absorbance and indicates the formation of a biofilm. 
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Impact on Established Biofilms 
Overnight biofilms were generated and incubated with 10µL of algal extract. Two 
measurements were taken to compare the overall biomass using CV stain with viable cells using 
MTT. Using a Dunnett test, each sample’s measurements were then compared to the control 
group to determine statistical significance at p < 0.05. With extract only treatments, there were 
no significant reductions in biomass, as evidenced by the CV percentages. B. braunii [H] (p  <  
0.001), B. braunii [M] (p < 0.001), C. danica [H] (p < 0.001), C. danica [M] (p = 0.001), N. 
oculata [H] (p < 0.001), and N. oculata [M] (p = 0.001) all showed statistically significant 
effects against viable cells as measured by their respective MTT percentages. 
Figure 19. Overnight treatment with algal extracts on established biofilms. Resulting static 
biofilm formation of S. maltophilia and cellular metabolism after treatment with algal extracts 
overnight. Ratios are generated to indicate general effectiveness of treatment against cells within 
the biofilm. * indicates statistically significant values at p <0 .05. 
 
Second, the algal extracts were applied in combination with the monobactam antibiotic, 






































   
 
acetonitrile (ACN), the algal extract medium. As in the previous data, the respective CV and 
MTT measurements were compared to their control groups to produce a percentage. The 
antibiotic control groups showed almost no change compared to the non-antibiotic control in the 
previous experiment, which was expected. Again, B. braunii [H] (p < 0.001), B. braunii [M] (p < 
0.001), C. danica [H] (p < 0.001), C. danica [M] (p = 0.003), N. oculata [H] (p < 0.001), and N. 
oculata [M] (p = 0.001) all showed statistically significant effects on cell viability. Interestingly, 
C. danica [H] (p = 0.04) showed statistically significant reductions in measurable biomass also 
with the addition of Aztreonam at the significance level of (p < 0.05) in the Dunnett’s analysis.  
 
Figure 20. Overnight treatment with algal extracts and aztreonam on established biofilms. 
Resulting static biofilm formation of S. maltophilia and cellular metabolism after treatment with 
algal extracts and aztreonam overnight. Ratios are generated to indicate general effectiveness of 
treatment against cells within the biofilm. * indicates statistically significant values at p < 0.05 









































   
 
Lastly, the cephalosporin, ceftriaxone at 64µg/mL, was used in combination with algal 
extracts. Again, the control group was treated with 64µg/mL of ceftriaxone only with 
acetonitrile. As in previous results, the CV and MTT measurements were compared to the 
control group to produce a percentage. Again, B. braunii [H] (p = 0.003), B. braunii [M] (p < 
0.001), C. danica [H] (p = 0.001), C. danica [M] (p = 0.005), N. oculata [H] (p < 0.001), and N. 
oculata [M] (p = 0.001) all showed statistically significant results against cell viability with 
reduced MTT percentages. 
Figure 21. Overnight treatment with algal extract and ceftriaxone on established biofilm. 
Resulting static biofilm formation of S. maltophilia and cellular metabolism after treatment with 
algal extracts and ceftriaxone overnight. Ratios are generated to indicate general effectiveness of 
treatment against cells within the biofilm. *indicates statistically significant values at p < 0 .05 
compared to control group of 64ug/mL of ceftriaxone only. 
 
Gentamycin was also tested. However, the sensitivity to gentamycin made it difficult to 
effectively evaluate statistically significant impacts. To test significant interactions between algal 
extracts and the addition of antibiotics against cell viability an ANOVA with a multiple 
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difference in cell viability across control groups—meaning antibiotics alone were not able to 
significantly reduce cell viability in established biofilms. N. oculata [M] showed statistically 
significant increase in reduction with the addition of ceftriaxone versus extract only reduction (p 
= 0.011); indicating an enhancement of ceftriaxone activity. No other statistical significance was 
found in determining enhancement activity of algal extracts with antibiotics. 
To understand if the observed effects in S. maltophilia biofilms could be applied to other 
film-forming organisms, C. albicans was tested in the same manner described for S. maltophilia. 
The extracts tested did not significantly impact the relative film mass accumulation by C. 
albicans either alone or in combination with fluconazole (see Appendix B). However, extracts 
from B. braunii, N. oculata, and C. danica improved sensitivity of established C. albicans 
biofilms to fluconazole. As shown in Figure 16, cell viability was significantly reduced relative 
to the fluconazole only control in the presence of extracts from these three algae. Treatment 
combinations with negative impacts on biofilm cell viability in C. albicans include combinations 
of 128µg/mL of fluconazole with extracts from C. danica [H] (p = 0.003) and N. oculata [H] (p 
= 0.006), [M] (p = 0.009); and combinations of 256µg/mL of fluconazole with extracts from B. 
braunii [M] (p = 0.004), C. danica [H] (p = 0.002), C. danica [M] (p = 0.021), and N. oculata 
[M] (p = 0.042). 
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Figure 22. Cell viability of C. albicans in established biofilms treated with algal extract and 
fluconazole. Measurements are based on MTT absorbances and are normalized to their 
respective control groups. For combined treatments, control groups were treated with acetonitrile 
or fluconazole only. 
 
The majority of treatments had little effect on cell viability, with many extracts only 
treatments increasing cell viability. However, there were a few extracts that showed a 
statistically significant reduction with higher concentrations of fluconazole. For treatments with 
extract and 128µg/mL of fluconazole, C. danica [H] (p = 0.003), N. oculata [H] (p = 0.006), N. 
oculata [M] (p = 0.009). For treatments with extract and 256µg/mL of fluconazole, B. braunii 
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Summary of Antimicrobial Effects 
 A summary of the antimicrobial effects by algal extracts observed in this study is 
presented in Table 6.  While the extracts did not exhibit strong growth inhibitory or bactericidal 
activity as single agents, the extracts in both solvent systems from B. braunii, C. Danica, and N. 
oculata caused significant decreases in S. maltophilia cell viability in biofilms when combined 
with either ceftriaxone or aztreonam. Extracts from these species also decreased cell viability in 
Candida biofilms when combined with fluconazole. Extracts from T. lutea and R. lens 
demonstrated limited impacts on either biofilm formation or antibiotic sensitivity of established 




   
 
Table 6. Summarization of Antimicrobial Effects 
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Planktonic Growth - + + - + + 
Biofilm Formation CV - - - - - - 
Extract Only 
CV - ++ + + - - 
MTT +++ +++ ++ ++ +++ ++ 
Extract + 
Aztreonam 
CV - + + + - - 
MTT +++ +++ ++ ++ +++ +++ 
Extract + 
Ceftriaxone 
CV + + + - - - 
MTT + +++ ++ ++ +++ +++ 
C
. albicans 
Extract Only CV - - - - - - MTT - - - - - - 
Extract + 64µg/mL 
fluconazole 
CV - - - - - - 




CV - - - - - - 




CV - - - - - - 
MTT - + + + + + 
Summarization of data for raw algal extracts. Only extracts with previous statistical significance 
are shown. A scale was used to present a visualization of performance across each test: ‘+’ = 
reduction of 25%, ‘++’ = reduction of 50%, and ‘+++’ = reduction of 75% or more. For 
planktonic growth, the greatest reduction percentage was used. 
 
The grouped scatter plot in Figure 17 shows a pairwise ratio of CV and MTT per extract based 
on extraction solvent and antibiotic combination for treatment. The overall distribution for the 
extraction solvent per treatment is similar, with the most noticeable difference of no antibiotic 
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(extract only). A statistical comparison of algal extracts based on extraction solvent using a 
Mann-Whitney U test was performed for each treatment condition in respect to CV and MTT 
percentages. Two scenarios were found to have been statistically different based on solvent: B. 
braunii CV for extract only treatment (p = 0.045) and C. danica CV for “extract + Aztreonam” 
(p = 0.030). All other instances showed no statistical significance between solvents per algae 




Figure 23. Solvent scatter plot of extract CV and MTT pairwise mean percentages grouped by 
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Discussion and Conclusion 
Extraction Solvents 
Commercialized chemical processes require large amounts of solvents. With modern 
safety regulations, many processes are being re-evaluated with a focus on reducing 
environmental impact and increasing efficiency. Dichloromethane, diethyl ether, 1-ethyl-3-
methylimidazolium methyl sulfate, benzene, petroleum ether, acetone, and chloroform have all 
been used as solvents and cosolvents to extract natural components, but most of these solvents 
are highly toxic to wildlife and pose serious health risks to humans.140–144 Alternative solvents 
that are safer and more renewably sourced such as 2-MTHF provide and attractive alternative to 
traditional extraction solvents.  
In the current study, two solvents were used in extraction of algal components, HIPA 
(3:1) and 2-MTHF. Extracted residue masses varied by species and solvent with the largest 
extracted masses seen with 2-MTHF from C. danica (14.6ug/mL), and the smallest extracted 
mass with HIPA from R. lens (3.6ug/mL). Based on mass, 2-MTHF produced generally higher 
yields than the HIPA except in the case of N. oculata (5.4ug/mL [M] and 5.6ug/mL [H]). As 
predicted, the higher yields of 2-MTHF was also associated with greater polyphenol 
concentration (p = 0.008). Improving polyphenol yield is important factor in future natural 
products research because their antimicrobial potential. These experiments demonstrate that the 
performance of 2-MTHF extracts in the antimicrobial assays described is comparable to the 
performance of the more traditional HIPA extracts. 
Impacts on S. maltophilia Biofilm Formation and Cell Viability in Established Biofilms 
Biofilm protection of nosocomial pathogens is responsible for many resistant hospital 
infections originating from implanted medical devices. Currently, the only way to treat such 
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infections is to remove the affected device because the film cannot be disrupted or penetrated 
with chemotherapy. For this reason, agents that can inhibit biofilm formation, alter biofilm 
metabolism, or increase sensitivity of biofilms to existing antimicrobial agents will constitute an 
important step in effectively treating biofilm-related infections. Reports describing anti-biofilm 
strategies have increased in frequency, indicating that this type of intervention will continue to 
be of interest amid escalations in resistant microbial infections.145,146  
Biofilm formation by S. maltophilia was not significantly impacted by the crude algal 
extracts tested (Table 5). However, biofilms treated with extracts from the oleaginous algae, B. 
braunii and N. oculata, and the heterotrophic algae, C. danica, showed significant decreases in 
cell viability relative to the untreated control (acetonitrile only). This effect was observed with 
extracts from both solvent systems and was essentially the same whether the extracts were used 
as single agents or in combination with aztreonam and ceftriaxone. Taken together, these results 
suggest that (i) the algal extracts did not significantly impact the access or interactions of the 
selected antibiotics with biofilm cells; and (ii) likely components of the extracts such as 
polyphenols, quorum signaling molecules, neutral lipids, and some classes of fatty acids, have 
bactericidal or bacteriostatic effects.23,68,70,118 
These data may also point to the involvement of S. maltophilia biofilm hydrophobicity in 
the observed effects of crude algal extracts on cell viability. Localized hydrophobic and 
hydrophilic regions are found in established bacterial biofilms.101 The hydrophobicity may be 
linked to discrete purposes such as water storage. Hydrophobic regions are more likely to 
interact with many of the organic components of the algal extracts such as fatty acids and less 
polar polyphenols. On the other hand, the antibiotics, aztreonam and ceftriaxone, while 
amphipathic overall, have high polar surface area (PSA) meaning they are more likely to interact 
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with hydrophilic regions. It’s possible that S. maltophilia produces largely hydrophobic ECM, 
allowing penetrance of the organic components but not the antibiotics. 
Impacts on C. albicans Cell Viability in Established Biofilms. 
C. albicans forms robust films that are difficult to remove or degrade. These yeast films 
have been shown to be highly hydrophobic due to the production, secretion, and branching of β-
1,3 glucan throughout the ECM.106 The branched polymers increase hydrophobicity which limits 
antifungal drug penetrance. Fluconazole it often used as a first line treatment for fungal 
infections, but biofilm associated C. albicans becomes exceedingly resistant. As reviewed by 
Desai et al., the biofilm is the single largest factor in resistance seen in C. albicans.28  
Algal extracts showed in this study demonstrated almost no effect on biofilm mass as 
measured by CV staining, on their own or combined with fluconazole. However, some of the 
extracts were effective in reducing cell viability in C. albicans biofilms. Interestingly, the 
extracts that reduced cell viability in S. maltophilia biofilms, namely those from B. braunii, N. 
oculata, and C. danica, were also effective in decreasing the cell viability of fluconazole-treated 
C. albicans biofilms. Extracts did not significantly impact cell viability of C. albicans when used 
as single agents but did increase sensitivity to fluconazole at higher concentrations (128 µg/mL 
and 256 µg/mL). These findings may strengthen the argument for hydrophobic interactions of 
extract components driving changes at the film surface, since the less polar structure of 
fluconazole (relative to ceftriaxone and aztreonam) could render it more interactive with 
nonpolar and amphipathic components of the extracts and thereby provide improved access for 
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APPENDIX A. DNA Isolation and 16S rRNA Profiling of Algal Cultures 
 
Algal cultures were evaluated for bacterial constituency at harvest by pelleting a 2 mL volume of 
culture and storing the pellet at -20°C for DNA isolation and PCR using amplification of 16S 
rRNA according to the method of Krohn-Molt.147 The results of this analysis for cultures 
extracted as described in these studies are given in Table AA1. 
 
Table A1. Bacterial Constituency in Algal Cultures for Extraction. 
 
Algal Culture 
Amplification of 16S rRNA Indicating the 
Presence of Bacteria 
T. lutea  positive 
R. lens  positive 
B. braunii  positive 
C. danica   positive 







   
 
APPENDIX B. Supplementary Data 
 
Figure B1. Impact of crude extracts on planktonic growth of S. maltophilia. All growth 

































Planktonic Growth of S. maltophilia Treated with Crude Extracts
Undiluted 1 to 1 1 to 10 1 to 100
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Figure B2. Comparison of sensitivity to antibiotic treatment planktonically vs. in an established 



























Comparison of Cell Viability after Treament Planktonically or in 




   
 
 
Figure B3. Impact of antibiotics on planktonic growth of S. maltophilia. All growth percentages 

























Planktonic Growth of S. maltophilia Treated with Antibotics 
256ug/ml 126ug/ml 64ug/ml 32ug/ml 16ug/ml
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Figure B4. Measured biomass of established C. albicans films treated with algal extracts and 
combined treatment with fluconazole. Measurements are based on CV absorbance and are 
normalized to their respective control groups. For combined treatments, control groups were 






































CV Absorbance of Treated C. albicans Biofilms
Extract Only 64ug/mL of Fluconazole
128ug/mL of Fluconazole 256ug/mL of Fluconazole
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APPENDIX C. Statistical Analyses 
 
Table C1. Kruskal-Wallis analysis of solvent by treatment, extract only versus extracts + 
128ug/mL of aztreonam. 
Test Statisticsa,b 
Algae Solvent CV MTT 
B. braunii HIPA Kruskal-Wallis H .006 .058 
df 1 1 
Asymp. Sig. .936 .810 
2-MTHF Kruskal-Wallis H 1.452 .161 
df 1 1 
Asymp. Sig. .228 .688 
C. danica HIPA Kruskal-Wallis H 5.026 .026 
df 1 1 
Asymp. Sig. .025 .873 
2-MTHF Kruskal-Wallis H .643 .103 
df 1 1 
Asymp. Sig. .423 .748 
N. oculata HIPA Kruskal-Wallis H .521 .162 
df 1 1 
Asymp. Sig. .470 .687 
2-MTHF Kruskal-Wallis H 2.084 .026 
df 1 1 
Asymp. Sig. .149 .872 
a. Kruskal Wallis Test 












   
 
Table C2. Kruskal-Wallis analysis of solvent by treatment, extract +128ug/mL versus 
extract + 64ug/mL of ceftriaxone. 
 
Test Statisticsa,b 
Algae Solvent CV MTT 
B. braunii HIPA Kruskal-Wallis H .006 .161 
df 1 1 
Asymp. Sig. .936 .688 
2-MTHF Kruskal-Wallis H 1.641 .940 
df 1 1 
Asymp. Sig. .200 .332 
C. danica HIPA Kruskal-Wallis H 6.564 .231 
df 1 1 
Asymp. Sig. .010 .631 
2-MTHF Kruskal-Wallis H 8.337 .234 
df 1 1 
Asymp. Sig. .004 .629 
N. oculata HIPA Kruskal-Wallis H 2.564 .058 
df 1 1 
Asymp. Sig. .109 .810 
2-MTHF Kruskal-Wallis H 2.084 .412 
df 1 1 
Asymp. Sig. .149 .521 
a. Kruskal Wallis Test 














   
 
Table C3. Kruskal-Wallis analysis of solvent by treatment, extract only versus extract + 
64ug/mL of ceftriaxone. 
Test Statisticsa,b 
Algae Solvent CV MTT 
B. braunii HIPA Kruskal-Wallis H .006 .006 
df 1 1 
Asymp. Sig. .936 .936 
2-MTHF Kruskal-Wallis H .232 .104 
df 1 1 
Asymp. Sig. .630 .747 
C. danica HIPA Kruskal-Wallis H .103 .316 
df 1 1 
Asymp. Sig. .749 .574 
2-MTHF Kruskal-Wallis H 2.837 .231 
df 1 1 
Asymp. Sig. .092 .631 
N. oculata HIPA Kruskal-Wallis H 1.859 .412 
df 1 1 
Asymp. Sig. .173 .521 
2-MTHF Kruskal-Wallis H .641 .234 
df 1 1 
Asymp. Sig. .423 .629 
a. Kruskal Wallis Test 















   
 
Table C4. ANOVA post-hoc Dunnett test comparing corresponding control groups to 
extracts and extracts with treatment against S. maltophilia. 
 
Multiple Comparisons 
Dunnett t (<control)a   
Solvent Treatment 
Dependen










HIPA Extract Only CV T. lutea Control 21.16667 .983 71.3824 
R. lens Control 36.50000 .998 86.7157 
B. braunii Control -40.00000 .124 10.2157 
C. danica Control -45.83333 .075 4.3824 
N. oculata Control -36.16667 .167 14.0491 
MTT T. lutea Control -31.66667 .109 6.5945 
R. lens Control -12.83333 .518 25.4278 
B. braunii Control -82.16667* .000 -43.9055 
C. danica Control -69.33333* .000 -31.0722 




CV T. lutea Control 5.83333 .906 52.3670 
R. lens Control -16.66667 .493 29.8670 
B. braunii Control -33.50000 .167 13.0337 
C. danica Control -67.50000* .004 -20.9663 
N. oculata Control -48.66667* .040 -2.1330 
MTT T. lutea Control -32.33333 .056 .8336 
R. lens Control -36.50000* .030 -3.3331 
B. braunii Control -77.50000* .000 -44.3331 
C. danica Control -69.00000* .000 -35.8331 




CV T. lutea Control 16.83333 .953 82.3827 
R. lens Control -31.33333 .368 34.2161 
B. braunii Control -9.33333 .717 56.2161 
C. danica Control -41.83333 .225 23.7161 
N. oculata Control -9.16667 .719 56.3827 
MTT T. lutea Control -44.50000* .029 -4.3707 
R. lens Control -51.00000* .012 -10.8707 
B. braunii Control -61.33333* .003 -21.2040 
C. danica Control -68.33333* .001 -28.2040 
N. oculata Control -86.00000* .000 -45.8707 
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2-MTHF Extract Only CV T. lutea Control 41.33333 .998 100.0748 
R. lens Control 49.33333 .999 108.0748 
B. braunii Control -64.83333* .030 -6.0919 
C. danica Control -48.33333 .111 10.4081 
N. oculata Control .16667 .835 58.9081 
MTT T. lutea Control -26.83333 .174 10.9762 
R. lens Control -24.16667 .224 13.6429 
B. braunii Control -89.83333* .000 -52.0238 
C. danica Control -61.83333* .001 -24.0238 




CV T. lutea Control 33.83333 .999 76.9529 
R. lens Control -9.00000 .652 34.1195 
B. braunii Control -71.50000* .001 -28.3805 
C. danica Control -56.83333* .009 -13.7138 
N. oculata Control -30.50000 .176 12.6195 
MTT T. lutea Control -29.83333 .156 10.5578 
R. lens Control -15.83333 .457 24.5578 
B. braunii Control -81.83333* .000 -41.4422 
C. danica Control -62.16667* .003 -21.7755 




CV T. lutea Control 42.83333 .999 91.6920 
R. lens Control -28.66667 .267 20.1920 
B. braunii Control -51.50000* .038 -2.6413 
C. danica Control -28.66667 .267 20.1920 
N. oculata Control 19.00000 .979 67.8587 
MTT T. lutea Control -49.33333* .023 -6.6864 
R. lens Control -22.16667 .327 20.4802 
B. braunii Control -87.66667* .000 -45.0198 
C. danica Control -60.33333* .005 -17.6864 
N. oculata Control -70.16667* .001 -27.5198 
*. The mean difference is significant at the 0.05 level. 







   
 
 
Table C5. Mann-Whitney U comparison of component concentration by extraction solvent. 
Test Statisticsa 
 Antioxidant Polyphenols Flavonoid 
Mann-Whitney U 6.000 0.000 12.000 
Wilcoxon W 21.000 15.000 27.000 
Z -1.358 -2.611 -0.104 
Asymp. Sig. (2-tailed) 0.175 0.009 0.917 
Exact Sig. [2*(1-tailed Sig.)] 0.222b 0.008 1.000b 
a. Grouping Variable: Solvent 
b. Not corrected for ties. 
 
 
Table C6. ANOVA post-hoc Dunnett test comparing control group to extracts with 
64ug/mL of fluconazole against C. albicans. 
 
 Extract Comparison 
Mean 
Difference Sig. 
95% (CI) Upper 
Bound 
D
unnett t (<control) b 
T. lutea [H] Control 0.4727 1.000 0.74492 
T. lutea [M] Control 0.0775 0.986 0.34876 
R. lens [H] Control 0.3831 1.000 0.65540 
R. lens [M] Control 0.7923 0.987 0.35104 
B. braunii [H] Control 1.0309* 0.994 0.37530 
B. braunii [M] Control -3.0607 0.024 -0.03385 
C. danica [H] Control -0.3855* 0.003 -0.11330 
C. danica [M] Control -0.2550 0.071 0.01716 
N. oculata [H] Control -0.3619* 0.006 -0.08977 
N. oculata [M] Control -0.3457* 0.009 -0.07356 
*The mean difference is significant at the 0.05 level. 





   
 
Table C7. ANOVA post-hoc Dunnett test comparing control group to extracts with 
128ug/mL of fluconazole against C. albicans. 
 
 Extract Comparison 
Mean 
Difference Sig. 
95% (CI) Upper 
Bound 
D
unnett t (<control) b 
T. lutea [H] Control 0.3692 1.000 0.74492 
T. lutea [M] Control 0.1832 1.000 0.34876 
R. lens [H] Control 0.1620 0.999 0.65540 
R. lens [M] Control 0.0530 0.975 0.35104 
B. braunii [H] Control 0.0291 0.954 0.37530 
B. braunii [M] Control -0.3592* 0.004 -0.03385 
C. danica [H] Control -0.3883* 0.002 -0.11330 
C. danica [M] Control -0.2995* 0.021 0.01716 
N. oculata [H] Control -0.2475 0.067 -0.08977 
N. oculata [M] Control -0.2696* 0.042 -0.07356 
*The mean difference is significant at the 0.05 level. 

























   
 
Table C8. C. albicans MTT ANOVA test by treatment, grouped by extraction solvent. 
ANOVA 
   
Species Solvent Sum of Squares df Mean 
Square 
F Sig. 
Control Control Between Groups .009 2 .004 .113 .893 
Within Groups .936 24 .039   
Total .945 26    
T. lutea HIPA Between Groups .011 2 .006 4.630 .061 
Within Groups .007 6 .001   
Total .018 8    
2-
MTHF 
Between Groups .045 2 .023 3.520 .097 
Within Groups .038 6 .006   
Total .084 8    
R. lens HIPA Between Groups .005 2 .002 1.373 .323 
Within Groups .010 6 .002   
Total .014 8    
2-
MTHF 
Between Groups .000 2 .000 .034 .967 
Within Groups .011 6 .002   
Total .011 8    
B. braunii HIPA Between Groups .000 2 .000 4.009 .078 
Within Groups .000 6 .000   
Total .000 8    
2-
MTHF 
Between Groups .000 2 .000 2.298 .182 
Within Groups .000 6 .000   
Total .000 8    
C. danica HIPA Between Groups .001 2 .000 1.961 .221 
Within Groups .001 6 .000   
Total .002 8    
2-
MTHF 
Between Groups .002 2 .001 1.767 .249 
Within Groups .004 6 .001   
Total .006 8    
N. 
oculata 
HIPA Between Groups .000 2 .000 .497 .631 
Within Groups .000 6 .000   
Total .001 8    
2-
MTHF 
Between Groups .004 2 .002 9.786 .013 
Within Groups .001 6 .000   
  Total .005 8    
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Table C9. Multiple Comparison analysis using Tukey HSD and Dunnett test for S. 











Control Control Tukey HSD No 
Antibiotic 
Aztreonam .03268888 .09310048 .934 .2651875 
Ceftriaxone .04223332 .09310048 .893 .2747319 
Aztreonam No Antibiotic -.03268888 .09310048 .934 .1998097 
Ceftriaxone .00954444 .09310048 .994 .2420431 
Ceftriaxone No Antibiotic -.04223332 .09310048 .893 .1902653 
Aztreonam -.00954444 .09310048 .994 .2229542 
Dunnett T3 No 
Antibiotic 
Aztreonam .03268888 .09706698 .981 .2908266 
Ceftriaxone .04223332 .09562820 .959 .2969348 
Aztreonam No Antibiotic -.03268888 .09706698 .981 .2254489 
Ceftriaxone .00954444 .08623426 .999 .2381008 
Ceftriaxone No Antibiotic -.04223332 .09562820 .959 .2124682 
Aztreonam -.00954444 .08623426 .999 .2190119 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic -.03268888 .09310048 .914 .1860421 
Ceftriaxone No Antibiotic -.04223332 .09310048 .863 .1764977 
T. lutea HIPA Tukey HSD No 
Antibiotic 
Aztreonam -.06550001 .02832428 .130 .0214067 
Ceftriaxone -.08126667 .02832428 .064 .0056400 
Aztreonam No Antibiotic .06550001 .02832428 .130 .1524067 
Ceftriaxone -.01576666 .02832428 .847 .0711400 
Ceftriaxone No Antibiotic .08126667 .02832428 .064 .1681733 
Aztreonam .01576666 .02832428 .847 .1026733 
Dunnett T3 No 
Antibiotic 
Aztreonam -.06550001 .03319070 .305 .0785623 
Ceftriaxone -.08126667 .03084062 .204 .0773878 
Aztreonam No Antibiotic .06550001 .03319070 .305 .2095623 
Ceftriaxone -.01576666 .01881562 .792 .0613290 
Ceftriaxone No Antibiotic .08126667 .03084062 .204 .2399211 
Aztreonam .01576666 .01881562 .792 .0928623 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic .06550001 .02832428 .103 .1465853 
Ceftriaxone No Antibiotic .08126667* .02832428 .050 .1623520 
2-
MTHF 
Tukey HSD No 
Antibiotic 
Aztreonam .14376667 .06540351 .150 .3444426 
Ceftriaxone .15606667 .06540351 .118 .3567426 
Aztreonam No Antibiotic -.14376667 .06540351 .150 .0569092 
Ceftriaxone .01229999 .06540351 .981 .2129759 
Ceftriaxone No Antibiotic -.15606667 .06540351 .118 .0446092 
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Aztreonam -.01229999 .06540351 .981 .1883759 
Dunnett T3 No 
Antibiotic 
Aztreonam .14376667 .07994726 .409 .6391663 
Ceftriaxone .15606667 .07968616 .367 .6569375 
Aztreonam No Antibiotic -.14376667 .07994726 .409 .3516330 
Ceftriaxone .01229999 .00956068 .559 .0520184 
Ceftriaxone No Antibiotic -.15606667 .07968616 .367 .3448041 
Aztreonam -.01229999 .00956068 .559 .0274184 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic -.14376667 .06540351 .119 .0434672 
Ceftriaxone No Antibiotic -.15606667 .06540351 .093 .0311672 
R. lens HIPA Tukey HSD No 
Antibiotic 
Aztreonam .04476667 .03318984 .422 .1466022 
Ceftriaxone .05006667 .03318984 .352 .1519022 
Aztreonam No Antibiotic -.04476667 .03318984 .422 .0570689 
Ceftriaxone .00530000 .03318984 .986 .1071355 
Ceftriaxone No Antibiotic -.05006667 .03318984 .352 .0517689 
Aztreonam -.00530000 .03318984 .986 .0965355 
Dunnett T3 No 
Antibiotic 
Aztreonam .04476667 .04059443 .673 .2958170 
Ceftriaxone .05006667 .04041899 .613 .3047969 
Aztreonam No Antibiotic -.04476667 .04059443 .673 .2062836 
Ceftriaxone .00530000 .00480555 .658 .0270941 
Ceftriaxone No Antibiotic -.05006667 .04041899 .613 .2046636 
Aztreonam -.00530000 .00480555 .658 .0164941 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic -.04476667 .03318984 .360 .0502476 
Ceftriaxone No Antibiotic -.05006667 .03318984 .295 .0449476 
2-
MTHF 
Tukey HSD No 
Antibiotic 
Aztreonam .00400000 .03495912 .993 .1112642 
Ceftriaxone .00906667 .03495912 .964 .1163308 
Aztreonam No Antibiotic -.00400000 .03495912 .993 .1032642 
Ceftriaxone .00506666 .03495912 .989 .1123308 
Ceftriaxone No Antibiotic -.00906667 .03495912 .964 .0981975 
Aztreonam -.00506666 .03495912 .989 .1021975 
Dunnett T3 No 
Antibiotic 
Aztreonam .00400000 .03911431 .999 .1748729 
Ceftriaxone .00906667 .03862196 .992 .1818146 
Aztreonam No Antibiotic -.00400000 .03911431 .999 .1668729 
Ceftriaxone .00506666 .02539361 .995 .1003199 
Ceftriaxone No Antibiotic -.00906667 .03862196 .992 .1636813 
Aztreonam -.00506666 .02539361 .995 .0901865 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic -.00400000 .03495912 .990 .0960792 
Ceftriaxone No Antibiotic -.00906667 .03495912 .952 .0910126 
HIPA Tukey HSD Aztreonam .00103334 .00438558 .970 .0144895 
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Ceftriaxone .01123333 .00438558 .094 .0246895 
Aztreonam No Antibiotic -.00103334 .00438558 .970 .0124228 
Ceftriaxone .01020000 .00438558 .127 .0236562 
Ceftriaxone No Antibiotic -.01123333 .00438558 .094 .0022228 
Aztreonam -.01020000 .00438558 .127 .0032562 
Dunnett T3 No 
Antibiotic 
Aztreonam .00103334 .00465140 .993 .0236994 
Ceftriaxone .01123333 .00507959 .236 .0321905 
Aztreonam No Antibiotic -.00103334 .00465140 .993 .0216327 
Ceftriaxone .01020000 .00320347 .098 .0232217 
Ceftriaxone No Antibiotic -.01123333 .00507959 .236 .0097239 
Aztreonam -.01020000 .00320347 .098 .0028217 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic -.00103334 .00438558 .960 .0115215 
Ceftriaxone No Antibiotic -.01123333 .00438558 .074 .0013215 
2-
MTHF 
Tukey HSD No 
Antibiotic 
Aztreonam -.00080000 .00461142 .984 .0133491 
Ceftriaxone .00813333 .00461142 .259 .0222824 
Aztreonam No Antibiotic .00080000 .00461142 .984 .0149491 
Ceftriaxone .00893334 .00461142 .209 .0230824 
Ceftriaxone No Antibiotic -.00813333 .00461142 .259 .0060158 
Aztreonam -.00893334 .00461142 .209 .0052158 
Dunnett T3 No 
Antibiotic 
Aztreonam -.00080000 .00528646 .998 .0322611 
Ceftriaxone .00813333 .00203087 .105 .0199117 
Aztreonam No Antibiotic .00080000 .00528646 .998 .0338611 
Ceftriaxone .00893334 .00563245 .452 .0370869 
Ceftriaxone No Antibiotic -.00813333 .00203087 .105 .0036451 
Aztreonam -.00893334 .00563245 .452 .0192202 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic .00080000 .00461142 .978 .0140013 
Ceftriaxone No Antibiotic -.00813333 .00461142 .212 .0050680 
C. 
danica 
HIPA Tukey HSD No 
Antibiotic 
Aztreonam -.00580000 .01281622 .895 .0335237 
Ceftriaxone .01850000 .01281622 .379 .0578237 
Aztreonam No Antibiotic .00580000 .01281622 .895 .0451237 
Ceftriaxone .02430000 .01281622 .220 .0636237 
Ceftriaxone No Antibiotic -.01850000 .01281622 .379 .0208237 
Aztreonam -.02430000 .01281622 .220 .0150237 
Dunnett T3 No 
Antibiotic 
Aztreonam -.00580000 .01494334 .968 .0737926 
Ceftriaxone .01850000 .00651869 .115 .0429993 
Aztreonam No Antibiotic .00580000 .01494334 .968 .0853926 
Ceftriaxone .02430000 .01506553 .446 .1025038 
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Ceftriaxone No Antibiotic -.01850000 .00651869 .115 .0059993 
Aztreonam -.02430000 .01506553 .446 .0539038 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic .00580000 .01281622 .866 .0424897 
Ceftriaxone No Antibiotic -.01850000 .01281622 .320 .0181897 
2-
MTHF 
Tukey HSD No 
Antibiotic 
Aztreonam -.01906666 .01973566 .623 .0414878 
Ceftriaxone .01803334 .01973566 .652 .0785878 
Aztreonam No Antibiotic .01906666 .01973566 .623 .0796211 
Ceftriaxone .03710000 .01973566 .224 .0976544 
Ceftriaxone No Antibiotic -.01803334 .01973566 .652 .0425211 
Aztreonam -.03710000 .01973566 .224 .0234544 
Dunnett T3 No 
Antibiotic 
Aztreonam -.01906666 .02353298 .806 .0753809 
Ceftriaxone .01803334 .01427974 .583 .0867445 
Aztreonam No Antibiotic .01906666 .02353298 .806 .1135142 
Ceftriaxone .03710000 .02026763 .383 .1475928 
Ceftriaxone No Antibiotic -.01803334 .01427974 .583 .0506778 
Aztreonam -.03710000 .02026763 .383 .0733928 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic .01906666 .01973566 .558 .0755649 
Ceftriaxone No Antibiotic -.01803334 .01973566 .589 .0384649 
N. 
oculata 
HIPA Tukey HSD No 
Antibiotic 
Aztreonam .00600000 .00725243 .701 .0282525 
Ceftriaxone .00650000 .00725243 .662 .0287525 
Aztreonam No Antibiotic -.00600000 .00725243 .701 .0162525 
Ceftriaxone .00050000 .00725243 .997 .0227525 
Ceftriaxone No Antibiotic -.00650000 .00725243 .662 .0157525 
Aztreonam -.00050000 .00725243 .997 .0217525 
Dunnett T3 No 
Antibiotic 
Aztreonam .00600000 .00613732 .721 .0323935 
Ceftriaxone .00650000 .00836381 .823 .0383162 
Aztreonam No Antibiotic -.00600000 .00613732 .721 .0203935 
Ceftriaxone .00050000 .00708331 1.000 .0332197 
Ceftriaxone No Antibiotic -.00650000 .00836381 .823 .0253162 
Aztreonam -.00050000 .00708331 1.000 .0322197 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic -.00600000 .00725243 .642 .0147619 
Ceftriaxone No Antibiotic -.00650000 .00725243 .600 .0142619 
2-
MTHF 
Tukey HSD No 
Antibiotic 
Aztreonam -.02160000 .01165965 .232 .0141750 
Ceftriaxone -.05136667* .01165965 .011 -.0155917 
Aztreonam No Antibiotic .02160000 .01165965 .232 .0573750 
Ceftriaxone -.02976667 .01165965 .095 .0060083 
Ceftriaxone No Antibiotic .05136667* .01165965 .011 .0871417 
Aztreonam .02976667 .01165965 .095 .0655417 
69 
 




Dunnett T3 No 
Antibiotic 
Aztreonam -.02160000 .01062811 .267 .0197654 
Ceftriaxone -.05136667* .01147422 .036 -.0051707 
Aztreonam No Antibiotic .02160000 .01062811 .267 .0629654 
Ceftriaxone -.02976667 .01277606 .191 .0183843 
Ceftriaxone No Antibiotic .05136667* .01147422 .036 .0975626 
Aztreonam .02976667 .01277606 .191 .0779177 
Dunnett t (2-
sided)a 
Aztreonam No Antibiotic .02160000 .01165965 .189 .0549787 
Ceftriaxone No Antibiotic .05136667* .01165965 .008 .0847453 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
